IPI 549

Drug Profile

IPI 549

Alternative Names: IPI-549

Latest Information Update: 06 Jan 2017

Price : $50

At a glance

  • Originator Intellikine
  • Developer Infinity Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase gamma inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 10 Nov 2016 Takeda and Infinity amended the agreement for products targeting delta and/or gamma isoforms of PI3K including duvelisib and IPI 549
  • 18 Apr 2016 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 01 Dec 2015 Phase-I clinical trials in Solid tumours (Monotherapy, Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT02637531)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top